Evofem Biosciences, Inc. products

EVO100 (the investigational name for Phexxi) is in development for two potential new indications, the prevention of urogenital chlamydia and urogenital gonorrhea in women, leveraging its vaginal pH modulator mechanism of action. Infection with these bacterial pathogens hEVO100 (the investigational name for Phexxi) is in development for two potential new indications, the prevention of urogenital chlamydia and urogenital gonorrhea in women, leveraging its vaginal pH modulator mechanism of action. Infection with these bacterial pathogens has been associated with a higher vaginal pH level. By maintaining a normal vaginal pH and working to keep vaginal pH in the 3.5-4.5 range, Phexxi creates an environment that is detrimental to their growth and proliferation.

We are collaborating with Orion Biotechnology to evaluate the compatibility and stability of Orion’s novel CCR5 antagonist, OB-002, in Phexxi with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of human immunodeficiency virus (HIV) in women. This collaboration will focus on determining compatibility and stability of OB-002 in Phexxi and is expected to yield results in the third quarter of 2022. Assuming positive results, the Company and Orion will seek government and philanthropic funding for subsequent clinical trials of the MPT vaginal gel product candidate.

EVO200 is an investigational vaginal pH modulator in development for the prevention of recurrent Bacterial Vaginosis (BV). In a Phase 1 dose-finding trial for this indication, the highest dose formulation of the study drug demonstrated reduced vaginal pH for up to seven days following a single administration. EVO200 has been designated a QIDP by the FDA for this indication.